|

Zanidatamab Clinical Trials

13 actively recruiting trials across 8 locations

No change since June 2026

Also known as: 2169946-15-8, Anti-HER2/HER2 Bispecific Antibody ZW25,, HER2 x HER2 Bispecific Antibody ZW25, ZANIDATAMAB, Zanidatamab-hrii, Ziihera, ZW-25, ZW25, JZP598, ZIIHERA®, ZW25 +2 more

Pipeline

Phase 1: 1Phase 2: 8Phase 3: 3Phase 1/2: 1

Top Sponsors

  • Jazz Pharmaceuticals4
  • UNICANCER2
  • QuantumLeap Healthcare Collaborative2
  • M.D. Anderson Cancer Center1
  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest1

Indications

  • Cancer13
  • Breast Cancer7
  • HER2-positive Breast Cancer3
  • HER-2 Protein Overexpression2
  • Metastatic Breast Cancer2

Other4 trials

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
Phase 2
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Phase 2
Personalized Medicine for Advanced Biliary Cancer Patients
Phase 3
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
Phase 2

Birmingham, Alabama2 trials

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

University of Alabama at Birmingham

Phase 2
PRE-I-SPY Phase I/Ib Oncology Platform Program

The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center

Phase 1

Phoenix, Arizona1 trial

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Mayo Clinic Scottsdale - PPDS

Phase 3

Prescott, Arizona1 trial

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Arizona Oncology Associates, PC - NAHOA

Phase 2

Cerritos, California1 trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

The Oncology Institute of Hope and Innovation

Phase 1/2

Duarte, California1 trial

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

City of Hope(City of Hope National Medical Center, City of Hope Medical Center)

Phase 3

Long Beach, California1 trial

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Oncology Institute

Phase 2

Atlanta, Georgia1 trial

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Emory University Hospital Midtown

Phase 2

Houston, Texas1 trial

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.